Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?

Zacks2024-12-24

Hologic, Inc. HOLX recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of laboratory-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493089333?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e","is_english":true,"pubTime":"2024-12-24 20:17","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493089333","market":"us","top_or_hot":-1,"title":"Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?","media":"Zacks","content":"<div>\n<p>Hologic, Inc. HOLX recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of laboratory-...</p>\n\n<a href=\"https://finance.yahoo.com/news/hologic-teams-cdc-combat-h5n1-121700228.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 20:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hologic-teams-cdc-combat-h5n1-121700228.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hologic, Inc. HOLX recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of laboratory-...</p>\n\n<a href=\"https://finance.yahoo.com/news/hologic-teams-cdc-combat-h5n1-121700228.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOLX","symbol_name":"豪洛捷","start_time":0,"source_url":"https://finance.yahoo.com/news/hologic-teams-cdc-combat-h5n1-121700228.html","article_id":"2493089333","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493089333","pubTimestamp":1735042620,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Hologic, Inc. HOLX recently entered into an agreement with the Centers for Disease Control and Prevention  to develop analyte-specific reagents  — the “active ingredients” of laboratory-developed tests aimed at detecting H5N1 bird flu. The ASRs are being developed on the company’s Panther Fusion system, a fully automated molecular testing platform that allows labs to quickly consolidate and run multiple assays for women's health, infectious disease and SARS-CoV-2  testing.The latest development builds on the company’s existing strong portfolio of diagnostic solutions, including assays used for the detection of COVID-19.Since the announcement on Dec. 18, HOLX shares edged up 0.3%, finishing at $72.50 yesterday. Hologic’s Panther Fusion SARS-CoV-2 assay and the Aptima SARS-CoV-2 assay have played a critical role in the global pandemic response, with the company continuing to innovate in this area. In 2023, it received the FDA’s clearance for a test that can detect SARS-CoV-2, influenza A","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HOLX":"豪洛捷","BK4588":"碎股","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4198":"医疗保健用品","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","PEN":"Penumbra Inc","BK4548":"巴美列捷福持仓","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","BK4585":"ETF&股票定投概念","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","BK4007":"制药","PAHC":"Phibro Animal Health Corporation","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","HAE":"美国血液技术","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4082":"医疗保健设备"},"translate_title":"Hologic与CDC合作抗击H5N1禽流感：股票会上涨吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1,"PAHC":1,"CDC":1,"HOLX":1,"HAE":0.9},"content_text":"Hologic, Inc. HOLX recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests aimed at detecting H5N1 bird flu. The ASRs are being developed on the company’s Panther Fusion system, a fully automated molecular testing platform that allows labs to quickly consolidate and run multiple assays for women's health, infectious disease and SARS-CoV-2 (COVID-19) testing.\nThe latest development builds on the company’s existing strong portfolio of diagnostic solutions, including assays used for the detection of COVID-19.\nPredicting HOLX Stock Movement Following the News\nSince the announcement on Dec. 18, HOLX shares edged up 0.3%, finishing at $72.50 yesterday. Hologic’s Panther Fusion SARS-CoV-2 assay and the Aptima SARS-CoV-2 assay have played a critical role in the global pandemic response, with the company continuing to innovate in this area. In 2023, it received the FDA’s clearance for a test that can detect SARS-CoV-2, influenza A and B and RSV in a single patient sample. We expect the latest development to positively boost market sentiment toward HOLX stock.\nHologic currently has a market capitalization of $16.26 billion. The company’s earnings yield of 5.99% compares favorably to the industry’s yield of - 4.65%. It delivered an earnings beat of 3.1%, on average, in the trailing four quarters.\nImportance Behind Hologic’s Latest Collaboration\nH5N1 bird flu, also known as avian influenza A (H5N1), is spreading among wild birds globally and causing outbreaks in poultry and dairy cows in the United States, with several recent cases reported among workers exposed to these infected animals. Illness from the virus in the United States has been mild but severe in other countries. To prepare for if the current outbreak worsens, Hologic is partnering with the CDC to develop reagents that may be used for H5N1 testing.\nThe contract will fund proof-of-concept development of ASRs — primers and probes in this case — that could eventually be incorporated into laboratory-developed tests (LDTs) designed to detect H5N1. While Hologic does not currently intend to make these ASRs commercially available, the company may explore future commercialization should the need for rapid implementation of H5N1 testing arise.\nImage Source: Zacks Investment Research\nAmong 1,700 Panther systems installed in the U.S. public health laboratories, hospitals and private reference laboratories, nearly 500 of them are Panther Fusion systems. These can generate more than 1,000 results in 24 hours and have the flexibility to rapidly scale up testing capacity without the need for additional instruments or operator training in the event of an outbreak or pandemic. The Open Access functionality on the system enables labs to develop and automate their LDTs with the FDA-approved in vitro diagnostic (IVD) assay workflows, reducing time and labor.\nMore Updates From Hologic\nAt the RSNA (Radiological Society of North America) 2024 Annual Meeting this month, Hologic presented new research demonstrating the favorable performance of its Genius AI Detection 2.0 software across diverse patient populations. The company also announced plans to introduce its next-generation Genius AI Detection PRO solution in the United States.\nIndustry Prospects Favoring Hologic\nPer a research report, the global poultry diagnostics market was valued at $772.4 million in 2023 and is projected to grow at a compound annual rate of 9.8% through 2030. One of the key factors driving the market’s growth is the increasing prevalence of poultry diseases, which has heightened the need for effective diagnostic solutions. Also, technological advancements in diagnostic tools have improved the accuracy and efficiency of disease detection.\nHOLX Stock Price Performance\nIn the past year, Hologic shares have risen 2% compared with the industry’s 4.2% growth.\nHOLX’s Zacks Rank & Key Picks\nHologic currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Penumbra PEN, Haemonetics HAE and Phibro Animal Health PAHC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nPenumbra shares have dropped 7% in the past year. Estimates for the company’s 2024 earnings per share have increased 2 cents to $2.81 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.\nEstimates for Haemonetics’ fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have dropped 12.3% in the past year against the industry’s growth of 11.2%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.\nEstimates for Phibro Animal Health’s fiscal 2025 earnings per share have increased 1.9% to $1.62 in the past 30 days. Shares of the company have surged 93% in the past year compared with the industry’s 11.1% rise. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHologic, Inc. (HOLX) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nPhibro Animal Health Corporation (PAHC) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493089333"}